Dewpoint Therapeutics
Jürgen Eckhardt is SVP and Head of Leaps by Bayer, which is the strategic venture capital unit of Bayer. The mission of Leaps is to invest in breakthrough technologies and disruptive business models in the areas of healthcare and agriculture. Jürgen is currently a board member of BlueRock, Joyn Bio, Dewpoint, Khloris, Oerth Bio, Immunitas and eGenesis. Before joining Bayer in 2016, Jürgen Eckhardt was head of the venture capital franchise at Bellevue Asset Management in Switzerland. Previously, he was a management consultant and Associate Partner with McKinsey & Co. in Zürich and New York and a member of the Healthcare Leadership Team. He began his career as a radiologist at the University Hospital of Basel, Switzerland. Jürgen received his M.D. from the University of Basel and his MBA from INSEAD in Fontainebleau, France.
This person is not in the org chart
This person is not in any offices
Dewpoint Therapeutics
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions has pathways that are regulated by condensates or arise from the dysfunction of condensates - including cancer, neurodegeneration, and metabolic disease.